Endoscopic submucosal dissection for early esophagogastric junction adenocarcinomas: a systematic review

Paul Doumbe-Mandengue; Anna Pellat; Benoît Terris; Frederic Beuvon; Mahaut Leconte; Anthony Dohan; Stanislas Chaussade; Romain Coriat; Maximilien Barret

Authors Paul Doumbe-Mandengue, Anna Pellat, Benoît Terris, Frederic Beuvon, Mahaut Leconte, Anthony Dohan, Stanislas Chaussade, Romain Coriat, Maximilien Barret.

Abstract

Background Esophagogastric junction adenocarcinomas (EGJAs) include esophageal and gastric cardia adenocarcinomas (GCAs). These tumors are currently regarded as a single entity, with similar surgical and oncological therapies, although they originate from different organs. Endoscopy allows an early-stage diagnosis, where both subtypes can be differentiated. With this review we aimed to describe the outcomes of endoscopic submucosal dissection for the treatment of esophageal adenocarcinomas (EAs) and GCAs.

Methods We identified studies by screening PubMed, Embase and Web of Science. We included all 19 studies that mentioned at least one of the following criteria of interest: en bloc; R0 resection; local recurrences; and/or overall survival.

Results We found an en bloc resection rate superior to 90% for both tumors. R0 resections rates were over 60% for most EAs, vs. 83% for most GCAs. We recorded less than 13% and 20% early and late adverse events for EA, and 10% and 7% for GCA. The local recurrence rate was 8% for EA and 3% for GCA. The overall survival was over 90%.

Conclusions Endoscopic submucosal dissection is safe and effective for esophageal and GCAs. These data support the extension of the use of endoscopic submucosal dissection to all EGJAs, including early EAs.

Keywords Esophagogastric junction adenocarcinoma, Barrett’s adenocarcinoma, gastric cardia adenocarcinoma, endoscopic submucosal dissection

Ann Gastroenterol 2022; 35 (4): 351-361